Categories: NewsPharmaceutical

BioIVT deployed IDBS E-WorkBook, reducing study times by at least 30%

WOKING, England, March 13, 2025 /PRNewswire/ — BioIVT, a leading provider of in vitro ADME research services, has successfully completed a collaboration with IDBS to implement the IDBS E-WorkBook platform, significantly reducing study times by at least 30%. The project has enabled BioIVT to enhance efficiency and responsiveness to its biopharmaceutical clients.

BioIVT sought a technological solution to enhance efficiency and maintain its reputation for responsiveness. The solution needed robust data processing and reporting capabilities to reduce study cycle times and increase capacity. Flexibility and user-friendliness were essential to promote adoption across multiple departments.

After evaluating various options, BioIVT selected the E-WorkBook for its comprehensive capabilities. IDBS worked closely with BioIVT to develop and implement the system, ensuring it met the critical needs of each department. Custom workflows were created to streamline processes and enhance efficiency.

The implementation of E-WorkBook led to significant process improvements across multiple departments. Efficiency gains of 40 to 70% were noted in activities such as documentation, data processing and addressing audit findings. The study director and maintenance and metrology teams experienced the most notable impact, with an overall reduction in time across all activities by at least 30%. This resulted in a 20% increase in capacity, equivalent to weekly time savings of approximately eight hours per user.

“Implementing the IDBS E-WorkBook platform has been transformative for our operations. The streamlined processes and increased efficiency have allowed us to deliver data to our clients at least four weeks faster. This collaboration with IDBS has truly enabled us to achieve our goals,” said Joanna Barbara, PhD, Kansas City Site Lead at BioIVT.

The full case study is available here.

Visit idbs.com, to learn more about IDBS.

About IDBS

IDBS helps BioPharma organizations unlock the potential of AI/ML to improve the lives of patients. As a trusted long-term partner to 80% of the top 20 global BioPharma companies1, IDBS delivers powerful cloud software and services specifically designed to meet the evolving needs of the BioPharma sector.

IDBS, a Danaher company, leverages 35 years of scientific informatics expertise to help organizations design, execute and orchestrate processes, manage, contextualize and structure data and gain valuable insights throughout the product lifecycle, from R&D through manufacturing. Known for its signature IDBS E-WorkBook software, IDBS has extended its flexible, scalable solutions to the IDBS Polar and PIMS cloud platforms to help scientists make smarter decisions with assured confidence in both GxP and non-GxP environments. 

1 Rank measured by Market Cap, Q1 2024.

Learn more at idbs.com.

About BioIVT

BioIVT enables smarter science and accelerates medical breakthroughs by delivering high-quality personalized biospecimen solutions and research services to the life science and diagnostic industries. We specialize in control and disease state samples including human and animal tissues or preparations, ADME-Tox products and research services, cell and gene therapy products, blood, and other biofluids. Our unmatched portfolio of clinical specimens directly supports precision medicine research and the effort to improve patient outcomes by coupling comprehensive clinical data with donor samples. By combining our technical expertise, exceptional customer service, and unparalleled access to biological specimens, BioIVT serves the research community as a trusted partner in ELEVATING SCIENCE®. For more information, please visit bioivt.com or follow us on LinkedIn.

MEDIA ENQUIRIES
 e |  mediaenquiries@idbs.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/bioivt-deployed-idbs-e-workbook-reducing-study-times-by-at-least-30-302401193.html

SOURCE IDBS

Staff

Recent Posts

AI-Era Position Statement to Protect the Integrity of Healthcare, Technology, and Services Benchmarking published by Black Book Research

Black Book outlines an AI-era integrity architecture for healthcare benchmarking, instrumentation hardening, tiered verification, real-time…

23 hours ago

New employee representative on the Board of Directors of Novo Nordisk A/S

Bagsværd, Denmark, 31 January 2026 – Thomas Rantzau, employee representative on the Board of Directors since…

23 hours ago

Embers to Empowerment: The Womb Room Reopens in Govans, Expanding Community-Centered Perinatal Care After Hampden Fire

Baltimore, Maryland, Jan. 31, 2026 (GLOBE NEWSWIRE) -- After sustaining water damage during the massive…

23 hours ago

Oxford Healthspan to Introduce New Primeadine® GF Powder Through a ‘Longevity Shot’ Experience During Grammy Week in Los Angeles

Science-Backed Spermidine Ritual Brings Cellular Renewal to a High-Performance Cultural Moment Primeadine Longevity Shot Primeadine…

23 hours ago

Enzon Announces Commencement of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock in Connection With Viskase Merger

CRANFORD, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“Enzon” or…

23 hours ago

Park Dental Partners Announces Dates for Fourth Quarter and Full Year 2025 Earnings Release and Conference Call

MINNEAPOLIS, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Park Dental Partners, Inc. (NASDAQ: PARK), a leading…

23 hours ago